Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...

As part of the new improvements, any sites where testing shows levels of elements that exceed accepted EGLE's environmental ...

Patients taking a standard dose of CagriSema lost 20.2% of their body weight after 84 weeks, compared with 23.6% for Lilly’s tirzepatide. “The trial did not achieve its primary endpoint of ...

For the past year, Dodge has tried to reset the Charger story around new hardware, new platforms, and a new era of ...

Ben Rhodes, a contributing Times Opinion writer, discusses why Trump waged war on Iran — and why his predecessors didn’t dare ...

The Rockets took the lead several times late in the game but couldn't hold on as Austin Westlake advanced to the state ...

MILAN (AP) — Ilia Malinin keeps teasing fans at the Milan Cortina Olympics by submitting program plans that have the American figure skating star attempting the quad axel, a 4 1/2-revolution jump so ...

Q4 2025 Earnings Call February 24, 2026 5:00 PM ESTCompany ParticipantsTryn Stimart - Chief Legal Officer, CCO, ...

Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.

Cash and Investments -- $301.8 million as of December 31, 2025, sufficient to fully fund current Phase III HCV and new HEV programs through 2027. Phase III HCV Trials -- C BEYOND enrollment completed ...

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis ...

The Inflation Reduction Act (IRA) represents a transformative shift in US health care policy by enabling Medicare to negotiate drug prices for high-expenditure medicatio ...